News 
Market Data 
Discover
Replies to post #4282406 on BB's Stock Haven
About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platforms. The Company's HIV vaccine for the clade B epidemic in the Americas and Europe is advancing in human trials conducted by the HIV Vaccine Trials Network. Preclinical programs are focused on preventive vaccines for Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections and cancers. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit https://www.geovax.com/.
"This as an important advance in the development of a vaccine with the potential to elicit broadly neutralizing antibody to the CD4 binding site," Dr. Robinson continued. "We intend to push this technology forward for the development of a vaccine for the clade C subtype of HIV that is devastating populations in Africa."
